Literature DB >> 10359840

Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A.

S H Soderling1, S J Bayuga, J A Beavo.   

Abstract

We report here the cloning, expression, and characterization of a dual-substrate, cAMP and cGMP, cyclic nucleotide phosphodiesterase (PDE) from mouse. This PDE contains the consensus sequence for a PDE catalytic domain, but shares <50% sequence identity with the catalytic domains of all other known PDEs and, therefore, represents a new PDE gene family, designated PDE10A. The cDNA for PDE10A is 3, 370 nt in length. It includes a full ORF, contains three in-frame stop codons upstream of the first methionine, and is predicted to encode a 779-aa enzyme. At the N terminus PDE10A has two GAF domains homologous to many signaling molecules, including PDE2, PDE5, and PDE6, which likely constitute a low-affinity binding site for cGMP. PDE10A hydrolyzes cAMP with a Km of 0.05 microM and cGMP with a Km of 3 microM. Although PDE10A has a lower Km for cAMP, the Vmax ratio (cGMP/cAMP) is 4.7. RNA distribution studies indicate that PDE10A is expressed at highest levels in testis and brain.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10359840      PMCID: PMC22059          DOI: 10.1073/pnas.96.12.7071

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

1.  The GAF domain: an evolutionary link between diverse phototransducing proteins.

Authors:  L Aravind; C P Ponting
Journal:  Trends Biochem Sci       Date:  1997-12       Impact factor: 13.807

2.  Generation and analysis of 280,000 human expressed sequence tags.

Authors:  L D Hillier; G Lennon; M Becker; M F Bonaldo; B Chiapelli; S Chissoe; N Dietrich; T DuBuque; A Favello; W Gish; M Hawkins; M Hultman; T Kucaba; M Lacy; M Le; N Le; E Mardis; B Moore; M Morris; J Parsons; C Prange; L Rifkin; T Rohlfing; K Schellenberg; M Bento Soares; F Tan; J Thierry-Meg; E Trevaskis; K Underwood; P Wohldman; R Waterston; R Wilson; M Marra
Journal:  Genome Res       Date:  1996-09       Impact factor: 9.043

3.  Characterization of fhlA mutations resulting in ligand-independent transcriptional activation and ATP hydrolysis.

Authors:  I Korsa; A Böck
Journal:  J Bacteriol       Date:  1997-01       Impact factor: 3.490

4.  Possible stimulation of retinal rod recovery to dark state by cGMP release from a cGMP phosphodiesterase noncatalytic site.

Authors:  A Yamazaki; V A Bondarenko; S Dua; M Yamazaki; J Usukura; F Hayashi
Journal:  J Biol Chem       Date:  1996-12-20       Impact factor: 5.157

5.  Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes.

Authors:  S A Ballard; C J Gingell; K Tang; L A Turner; M E Price; A M Naylor
Journal:  J Urol       Date:  1998-06       Impact factor: 7.450

Review 6.  Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms.

Authors:  J A Beavo
Journal:  Physiol Rev       Date:  1995-10       Impact factor: 37.312

7.  Attenuation of insulin secretion by insulin-like growth factor 1 is mediated through activation of phosphodiesterase 3B.

Authors:  A Z Zhao; H Zhao; J Teague; W Fujimoto; J A Beavo
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

8.  Identification of key amino acids in a conserved cGMP-binding site of cGMP-binding phosphodiesterases. A putative NKXnD motif for cGMP binding.

Authors:  I V Turko; T L Haik; L M McAllister-Lucas; F Burns; S H Francis; J D Corbin
Journal:  J Biol Chem       Date:  1996-09-06       Impact factor: 5.157

9.  Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction.

Authors:  M Boolell; M J Allen; S A Ballard; S Gepi-Attee; G J Muirhead; A M Naylor; I H Osterloh; C Gingell
Journal:  Int J Impot Res       Date:  1996-06       Impact factor: 2.896

10.  An essential aspartic acid at each of two allosteric cGMP-binding sites of a cGMP-specific phosphodiesterase.

Authors:  L M McAllister-Lucas; T L Haik; J L Colbran; W K Sonnenburg; D Seger; I V Turko; J A Beavo; S H Francis; J D Corbin
Journal:  J Biol Chem       Date:  1995-12-22       Impact factor: 5.157

View more
  98 in total

1.  Cloning and characterization of PDE7B, a cAMP-specific phosphodiesterase.

Authors:  J M Hetman; S H Soderling; N A Glavas; J A Beavo
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

2.  Identification of a novel isoform of the cyclic-nucleotide phosphodiesterase PDE3A expressed in vascular smooth-muscle myocytes.

Authors:  Y H Choi; D Ekholm; J Krall; F Ahmad; E Degerman; V C Manganiello; M A Movsesian
Journal:  Biochem J       Date:  2001-01-01       Impact factor: 3.857

3.  T cell activation up-regulates cyclic nucleotide phosphodiesterases 8A1 and 7A3.

Authors:  N A Glavas; C Ostenson; J B Schaefer; V Vasta; J A Beavo
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-22       Impact factor: 11.205

4.  Activation of PDE10 and PDE11 phosphodiesterases.

Authors:  Ronald Jäger; Corina Russwurm; Frank Schwede; Hans-Gottfried Genieser; Doris Koesling; Michael Russwurm
Journal:  J Biol Chem       Date:  2011-11-21       Impact factor: 5.157

Review 5.  TAK-063, a novel PDE10A inhibitor with balanced activation of direct and indirect pathways, provides a unique opportunity for the treatment of schizophrenia.

Authors:  Kazunori Suzuki; Haruhide Kimura
Journal:  CNS Neurosci Ther       Date:  2018-01-09       Impact factor: 5.243

6.  Selective blockade of phosphodiesterase types 2, 5 and 9 results in cyclic 3'5' guanosine monophosphate accumulation in retinal pigment epithelium cells.

Authors:  R M H Diederen; E C La Heij; M Markerink-van Ittersum; A Kijlstra; F Hendrikse; J de Vente
Journal:  Br J Ophthalmol       Date:  2006-08-30       Impact factor: 4.638

Review 7.  Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies.

Authors:  Adam Lerner; Paul M Epstein
Journal:  Biochem J       Date:  2006-01-01       Impact factor: 3.857

8.  Phosphodiesterase 10A Is Tethered to a Synaptic Signaling Complex in Striatum.

Authors:  Corina Russwurm; Doris Koesling; Michael Russwurm
Journal:  J Biol Chem       Date:  2015-03-11       Impact factor: 5.157

9.  Synthesis and in vitro biological evaluation of pyrazole group-containing analogues for PDE10A.

Authors:  Junfeng Li; Hongjun Jin; Haiying Zhou; Justin Rothfuss; Zhude Tu
Journal:  Medchemcomm       Date:  2013-02-01       Impact factor: 3.597

Review 10.  The role of phosphodiesterases in schizophrenia : therapeutic implications.

Authors:  Judith A Siuciak
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.